CTOs on the Move

Counsyl

www.counsyl.com

 
Counsyl is a DNA testing and genetic counseling service that offers genetic screening for men, women and their children. Our philosophy is simple - focus on diseases where advanced knowledge makes a difference in health outcomes, whether it`s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead. Counsyl has screened over 750,000 patients and served over 10,000 health professionals in its modern clinical laboratory. From the purely mechanical to profoundly human, Counsyl strives to make genetic screening truly accessible to everyone. The team consists of world class engineers, scientists and clinical experts as well as a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.counsyl.com
  • 180 Kimball Way
    South San Francisco, CA USA 94080
  • Phone: 888.268.6795

Executives

Name Title Contact Details

Funding

Counsyl raised $80M on 11/06/2017

Similar Companies

New Chapter

New Chapter, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. New Chapter, Inc. is based in Brattleboro, VT. You can find more information on New Chapter, Inc. at www.new-chapter.com

MedCare Investment Funds

MedCare and its affiliated entities manage approximately $1 billion in assets, the substantial majority of which are related to the medical and healthcare services industry.

Spokane Mental health

Since 1970, Spokane Mental Health, a not-for-profit organization, has served children, families, adults and elders throughout Spokane County.

Symbion Research International

Symbion Research International is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plasmatech Biopharmaceuticals

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.